Cargando…

Bromodomain and extra-terminal domain (BET) proteins regulate melanocyte differentiation

BACKGROUND: Pharmacologic inhibition of bromodomain and extra-terminal (BET) proteins is currently being explored as a new therapeutic approach in cancer. Some studies have also implicated BET proteins as regulators of cell identity and differentiation through their interactions with lineage-specifi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Trivedi, Archit, Mehrotra, Aanchal, Baum, Caitlin E., Lewis, Brandon, Basuroy, Tupa, Blomquist, Thomas, Trumbly, Robert, Filipp, Fabian V., Setaluri, Vijayasaradhi, de la Serna, Ivana L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7063807/ https://www.ncbi.nlm.nih.gov/pubmed/32151278 http://dx.doi.org/10.1186/s13072-020-00333-z

Ejemplares similares

Epigenetic and pharmacological control of pigmentation via Bromodomain Protein 9 (BRD9)
por: Basuroy, Tupa, et al.
Publicado: (2022)

BRG1 interacts with SOX10 to establish the melanocyte lineage and to promote differentiation
por: Marathe, Himangi G., et al.
Publicado: (2017)

The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins
por: Taniguchi, Yasushi
Publicado: (2016)

Bioactivation of Isoxazole-Containing Bromodomain and Extra-Terminal Domain (BET) Inhibitors
por: Flynn, Noah R., et al.
Publicado: (2021)

Bromodomain and Extra-Terminal (BET) Domain Protein Inhibitors for Solid Tumor Cancers
por: Nguyen, Martin V., et al.
Publicado: (2020)

Discovery of Benzo[d]imidazole‐6‐sulfonamides as Bromodomain and Extra‐Terminal Domain (BET) Inhibitors with Selectivity for the First Bromodomain
por: Cipriano, Alessandra, et al.
Publicado: (2022)

Anticancer Effects of I-BET151, an Inhibitor of Bromodomain and Extra-Terminal Domain Proteins
por: Lai, Jiacheng, et al.
Publicado: (2021)

Bromodomain and Extra-Terminal Proteins in Brain Physiology and Pathology: BET-ing on Epigenetic Regulation
por: Martella, Noemi, et al.
Publicado: (2023)

Suppression of interferon β gene transcription by inhibitors of bromodomain and extra-terminal (BET) family members
por: Malik, Nazma, et al.
Publicado: (2015)

Selective inhibition of BET bromodomains
por: Filippakopoulos, Panagis, et al.
Publicado: (2010)

Bromodomain and extra-terminal (BET) proteins target Moloney murine leukemia virus integration to transcription start sites
por: De Riick, Jan, et al.
Publicado: (2013)

Deacetylase inhibitors repress STAT5-mediated transcription by interfering with bromodomain and extra-terminal (BET) protein function
por: Pinz, Sophia, et al.
Publicado: (2015)

77232 The role of the bromodomain and extra-terminal motif (BET) family of proteins in head and neck cancer tumorigenic phenotype
por: Sample, Reilly A., et al.
Publicado: (2021)

Critical role of miR-10b in B-Raf(V600E) dependent anchorage independent growth and invasion of melanoma cells
por: Datar, Ila, et al.
Publicado: (2019)

BRG1 promotes survival of UV-irradiated melanoma cells by cooperating with MITF to activate the melanoma inhibitor of apoptosis gene
por: Saladi, Srinivas V, et al.
Publicado: (2013)

Bromodomain and Extra Terminal (BET) Inhibitor Suppresses Macrophage-Driven Steroid-Resistant Exacerbations of Airway Hyper-Responsiveness and Inflammation
por: Nguyen, Thi Hiep, et al.
Publicado: (2016)

Development of a Novel Positron Emission Tomography (PET) Radiotracer Targeting Bromodomain and Extra-Terminal Domain (BET) Family Proteins
por: Bai, Ping, et al.
Publicado: (2020)

Targeting BET bromodomain proteins in solid tumors
por: Sahai, Vaibhav, et al.
Publicado: (2016)

Impact of Target Warhead and Linkage Vector on Inducing Protein Degradation: Comparison of Bromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine (JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor Scaffolds
por: Chan, Kwok-Ho, et al.
Publicado: (2017)

Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression
por: Zhou, Bing, et al.
Publicado: (2017)

Bromodomains and Extra-Terminal (BET) Inhibitor JQ1 Suppresses Proliferation of Acute Lymphocytic Leukemia by Inhibiting c-Myc-Mediated Glycolysis
por: Zhang, Meng-Yi, et al.
Publicado: (2020)

tBRD-1 Selectively Controls Gene Activity in the Drosophila Testis and Interacts with Two New Members of the Bromodomain and Extra-Terminal (BET) Family
por: Theofel, Ina, et al.
Publicado: (2014)

New Synthetic Routes to Triazolo-benzodiazepine Analogues: Expanding the Scope of the Bump-and-Hole Approach for Selective Bromo and Extra-Terminal (BET) Bromodomain Inhibition
por: Baud, Matthias G. J., et al.
Publicado: (2015)

BET bromodomain proteins are required for glioblastoma cell proliferation
por: Pastori, Chiara, et al.
Publicado: (2014)

When are the BET factors the most sensitive to bromodomain inhibitors?
por: Khochbin, Saadi
Publicado: (2013)

Bromodomain Blockade for Intimal Hyperplasia — A Good BET?
por: Ostriker, Allison C., et al.
Publicado: (2015)

BET bromodomain inhibitor (JQ1) and tumor angiogenesis
por: Bid, Hemant Kumar, et al.
Publicado: (2016)

BET bromodomain inhibitors synergize with ATR inhibitors in melanoma
por: Veppil Muralidharan, Somsundar, et al.
Publicado: (2017)

BET bromodomain inhibitors synergize with ATR inhibitors in melanoma
por: Muralidharan, Somsundar Veppil, et al.
Publicado: (2017)

Chemical probes and inhibitors of bromodomains outside the BET family
por: Moustakim, Moses, et al.
Publicado: (2016)

Selective BET bromodomain inhibition as an antifungal therapeutic strategy
por: Mietton, Flore, et al.
Publicado: (2017)

Interactome Rewiring Following Pharmacological Targeting of BET Bromodomains
por: Lambert, Jean-Philippe, et al.
Publicado: (2019)

Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition
por: Mao, Wendy, et al.
Publicado: (2019)

Prognostic Significance of Melanoma Differentiation and Trans-Differentiation
por: Maddodi, Nityanand, et al.
Publicado: (2010)

Metabolism of JQ1, an inhibitor of bromodomain and extra terminal bromodomain proteins, in human and mouse liver microsomes
por: Li, Feng, et al.
Publicado: (2020)

Roles of Bromodomain Extra Terminal Proteins in Metabolic Signaling and Diseases
por: Wu, Dayu, et al.
Publicado: (2022)

EPAC mediates the dual role of cAMP signaling in melanoma
por: Rodriguez, Carlos I., et al.
Publicado: (2018)

Role of the Skin Microenvironment in Melanomagenesis: Epidermal Keratinocytes and Dermal Fibroblasts Promote BRAF Oncogene-Induced Senescence Escape in Melanocytes
por: Sadangi, Shreyans, et al.
Publicado: (2022)

BET bromodomain inhibition suppresses T(H)17-mediated pathology
por: Mele, Deanna A., et al.
Publicado: (2013)

BET bromodomain protein inhibition is a therapeutic option for medulloblastoma
por: Henssen, Anton, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_6nvifp68kqj9l8qgcf0t02jonm